IL138746A - Assay for diagnosis of schizophrenia based on a new peptide - Google Patents
Assay for diagnosis of schizophrenia based on a new peptideInfo
- Publication number
- IL138746A IL138746A IL138746A IL13874600A IL138746A IL 138746 A IL138746 A IL 138746A IL 138746 A IL138746 A IL 138746A IL 13874600 A IL13874600 A IL 13874600A IL 138746 A IL138746 A IL 138746A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- peptide
- peptides
- binding
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 116
- 201000000980 schizophrenia Diseases 0.000 title claims description 20
- 238000003745 diagnosis Methods 0.000 title claims description 12
- 238000003556 assay Methods 0.000 title description 12
- 230000027455 binding Effects 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- 239000012634 fragment Substances 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 50
- 230000000698 schizophrenic effect Effects 0.000 description 41
- 235000001014 amino acid Nutrition 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 18
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 18
- 229940127236 atypical antipsychotics Drugs 0.000 description 15
- 230000000692 anti-sense effect Effects 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 8
- 108010050848 glycylleucine Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- JHNOXVASMSXSNB-WEDXCCLWSA-N Lys-Thr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JHNOXVASMSXSNB-WEDXCCLWSA-N 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- FOEHRHOBWFQSNW-KATARQTJSA-N Leu-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)N)O FOEHRHOBWFQSNW-KATARQTJSA-N 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 5
- 108010061238 threonyl-glycine Proteins 0.000 description 5
- DYJJJCHDHLEFDW-FXQIFTODSA-N Ala-Pro-Cys Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N DYJJJCHDHLEFDW-FXQIFTODSA-N 0.000 description 4
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 230000000702 anti-platelet effect Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000004623 platelet-rich plasma Anatomy 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000006862 enzymatic digestion Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 2
- 101710159793 Extracellular calcium-sensing receptor Proteins 0.000 description 2
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 2
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
- 101710113670 Anaerobic glycerol-3-phosphate dehydrogenase subunit A Proteins 0.000 description 1
- 101710113668 Anaerobic glycerol-3-phosphate dehydrogenase subunit C Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 description 1
- 102100031237 Cystatin-A Human genes 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014557 Emotional poverty Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- YIFUFYZELCMPJP-YUMQZZPRSA-N Gly-Leu-Cys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(O)=O YIFUFYZELCMPJP-YUMQZZPRSA-N 0.000 description 1
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000921786 Homo sapiens Cystatin-A Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KVSBQLNBMUPADA-AVGNSLFASA-N Leu-Val-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KVSBQLNBMUPADA-AVGNSLFASA-N 0.000 description 1
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- ALJGSKMBIUEJOB-FXQIFTODSA-N Pro-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 ALJGSKMBIUEJOB-FXQIFTODSA-N 0.000 description 1
- HXNYBZQLBWIADP-WDSKDSINSA-N Pro-Cys Chemical compound OC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1 HXNYBZQLBWIADP-WDSKDSINSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- -1 amine acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL138746A IL138746A (en) | 1998-04-02 | 2000-09-28 | Assay for diagnosis of schizophrenia based on a new peptide |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12392598 | 1998-04-02 | ||
| PCT/IL1999/000190 WO1999051725A2 (en) | 1998-04-02 | 1999-03-30 | Assay for the diagnosis of schizophrenia based on a new peptide |
| IL138746A IL138746A (en) | 1998-04-02 | 2000-09-28 | Assay for diagnosis of schizophrenia based on a new peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL138746A true IL138746A (en) | 2006-12-10 |
Family
ID=11071395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL138746A IL138746A (en) | 1998-04-02 | 2000-09-28 | Assay for diagnosis of schizophrenia based on a new peptide |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7098304B1 (https=) |
| EP (1) | EP1068303B1 (https=) |
| JP (1) | JP4364433B2 (https=) |
| CN (1) | CN1171995C (https=) |
| AR (1) | AR014811A1 (https=) |
| AT (1) | ATE309335T1 (https=) |
| AU (1) | AU3165599A (https=) |
| BR (1) | BR9909308B1 (https=) |
| CA (1) | CA2324380C (https=) |
| DE (1) | DE69928236T2 (https=) |
| IL (1) | IL138746A (https=) |
| TW (1) | TW581812B (https=) |
| WO (1) | WO1999051725A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1331481A4 (en) * | 2000-10-31 | 2005-06-29 | Japan Government | KIT FOR THE DIAGNOSIS OF SCHIZOPHRENIA |
| EP1415162B1 (en) * | 2001-03-21 | 2011-05-11 | Yeda Research And Development Co., Ltd. | Novel peptides for the diagnosis of schizophrenia |
| CN1300588C (zh) * | 2005-02-28 | 2007-02-14 | 上海交通大学 | 用于精神分裂症诊断的血浆特异性蛋白获取方法及应用 |
| WO2007091881A2 (en) * | 2005-04-29 | 2007-08-16 | Leiden University Medical Center | Methods and means for detection of mycobacterium leprae infections |
| ES3038398T3 (en) * | 2015-07-14 | 2025-10-13 | Yeda Res & Dev | Peptide combinations for use in the diagnosis of schizophrenia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6913994A (en) | 1993-05-13 | 1994-12-12 | New York University | Psychosis protecting nucleic acid, peptides, compositions and method of use |
| US6008001A (en) * | 1993-11-05 | 1999-12-28 | Yeda Research And Development Co. Ltd. | Diagnosis of the susceptibility of contracting schizophrenia |
| AU695043B2 (en) | 1994-03-01 | 1998-08-06 | Yeda Research And Development Co. Ltd. | Assay for the diagnosis of schizophrenia |
-
1999
- 1999-03-30 EP EP99913557A patent/EP1068303B1/en not_active Expired - Lifetime
- 1999-03-30 AU AU31655/99A patent/AU3165599A/en not_active Abandoned
- 1999-03-30 CA CA002324380A patent/CA2324380C/en not_active Expired - Fee Related
- 1999-03-30 US US09/647,457 patent/US7098304B1/en not_active Expired - Lifetime
- 1999-03-30 WO PCT/IL1999/000190 patent/WO1999051725A2/en not_active Ceased
- 1999-03-30 DE DE69928236T patent/DE69928236T2/de not_active Expired - Lifetime
- 1999-03-30 CN CNB998059951A patent/CN1171995C/zh not_active Expired - Fee Related
- 1999-03-30 BR BRPI9909308-1A patent/BR9909308B1/pt not_active IP Right Cessation
- 1999-03-30 AT AT99913557T patent/ATE309335T1/de not_active IP Right Cessation
- 1999-03-30 JP JP2000542438A patent/JP4364433B2/ja not_active Expired - Lifetime
- 1999-03-31 TW TW088105128A patent/TW581812B/zh not_active IP Right Cessation
- 1999-03-31 AR ARP990101492A patent/AR014811A1/es not_active Application Discontinuation
-
2000
- 2000-09-28 IL IL138746A patent/IL138746A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2324380C (en) | 2009-02-24 |
| ATE309335T1 (de) | 2005-11-15 |
| BR9909308A (pt) | 2001-10-02 |
| HK1030966A1 (en) | 2001-05-25 |
| WO1999051725A2 (en) | 1999-10-14 |
| CN1300320A (zh) | 2001-06-20 |
| EP1068303A2 (en) | 2001-01-17 |
| DE69928236D1 (de) | 2005-12-15 |
| JP2002510712A (ja) | 2002-04-09 |
| WO1999051725A3 (en) | 1999-12-02 |
| AU3165599A (en) | 1999-10-25 |
| BR9909308B1 (pt) | 2010-11-30 |
| EP1068303B1 (en) | 2005-11-09 |
| JP4364433B2 (ja) | 2009-11-18 |
| US7098304B1 (en) | 2006-08-29 |
| CA2324380A1 (en) | 1999-10-14 |
| AR014811A1 (es) | 2001-03-28 |
| TW581812B (en) | 2004-04-01 |
| CN1171995C (zh) | 2004-10-20 |
| DE69928236T2 (de) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schellekens et al. | Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. | |
| Chaponnier et al. | The actin filament-severing domain of plasma gelsolin. | |
| AU689777B2 (en) | Assay for cardiac troponin I | |
| McDONALD et al. | Properties and distribution of the protein inhibitor (M r 17,000) of protein kinase C | |
| WO1992007068A1 (en) | Amyloidin protease and uses thereof | |
| EP1068303B1 (en) | Peptide for use in the diagnosis of schizophrenia | |
| AU3958795A (en) | Antibiotic cryptdin peptides and methods of their use | |
| CN108948153B (zh) | 一种瓜氨酸修饰肽抗原组合及其应用 | |
| US20110171751A1 (en) | Recombinant polypeptides for diagnosing infection with trypanosoma cruzi | |
| AU621943B2 (en) | Determining cereal quality | |
| CN108948173B (zh) | 一种瓜氨酸修饰肽及其应用 | |
| WO1991007510A1 (en) | A method of detecting htlv-i antibodies in human body fluids | |
| HK1030966B (en) | Peptide for use in the diagnosis of schizophrenia | |
| EP1051487A1 (en) | Placental protein 13 | |
| Laine et al. | Identification of the discontinuous epitope in human complement protein C9 recognized by anti-melittin antibodies. | |
| WO2004019045A2 (en) | Method for the diagnosis of alzheimer disease | |
| CA2441925C (en) | Novel peptides for the diagnosis of schizophrenia | |
| US7491515B2 (en) | Recombinant polypeptides for diagnosing infection with Trypanosoma cruzi | |
| EP1614692B1 (en) | ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis | |
| Deckmann et al. | A conformational epitope which detects autoantibodies from schizophrenic patients | |
| US6300139B1 (en) | FTCD antigen | |
| CN108948174B (zh) | 一种瓜氨酸修饰肽及其应用 | |
| Christensen et al. | Mapping of monoclonal antibody epitopes in the nucleolar protein fibrillarin (B-36) of Physarum polycephalum | |
| AU2002241232A1 (en) | Novel peptides for the diagnosis of schizophrenia | |
| EP1130030A1 (en) | Human erythroid differentiation related factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |